Medical Science 2021 Paper I 50 marks Describe

Q7

(a) Define poison and classify it. Describe the treatment of venomous snakebite. Write a note on 'designer drug'. 15 marks (b) (i) Enumerate predisposing conditions for oral cancer. Describe the pathogenesis, molecular basis and morphology of oral cancer. 10 marks (ii) Describe the pathologic responses of the glomerulus to injury and pathogenesis of glomerulonephritis. 10 marks (c) (i) Elaborate the mechanisms of antimicrobial resistance. 10 marks (ii) Name the third and fourth generation cephalosporins. Mention their therapeutic indications. 5 marks

हिंदी में प्रश्न पढ़ें

(a) विष को परिभाषित और वर्गीकृत कीजिए। विषैले सर्पदंश के उपचार का वर्णन कीजिए। 'डिजाइनर ड्रग' पर एक टिप्पणी लिखिए। 15 (b) (i) मुख कैंसर की प्रवर्तनपूर्व अवस्थाओं को गिनाइए। मुख कैंसर के रोगजनन, आणविक आधार तथा आकृतिक लक्षणों का वर्णन कीजिए। 10 (ii) केशिकात्वक में होने वाली उन विकृतिजन्य अनुक्रियाओं का वर्णन कीजिए, जो उसमें स्तवकबुकशोथ से पहुँची क्षति और स्तवकबुकशोथजनन से उत्पन्न होती हैं। 10 (c) (i) प्रतिरोगाणु प्रतिरोध की क्रियाविधियों का वर्णन कीजिए। 10 (ii) सिफेलोस्पोरिन की तृतीय और चतुर्थ पीढ़ी की दवाओं के नाम गिनाइए। उनके चिकित्सार्थ संकेतों को उल्लिखित कीजिए। 5

Evaluate your answer to this question → See all 2021 Medical Science questions

Directive word: Describe

This question asks you to describe. The directive word signals the depth of analysis expected, the structure of your answer, and the weight of evidence you must bring.

See our UPSC directive words guide for a full breakdown of how to respond to each command word.

How this answer will be evaluated

Approach

The directive 'describe' demands systematic, detailed exposition across all sub-parts. Allocate approximately 30% time/words to part (a) [15 marks], 20% to (b)(i) [10 marks], 20% to (b)(ii) [10 marks], 20% to (c)(i) [10 marks], and 10% to (c)(ii) [5 marks]. Structure: begin each sub-part with precise definitions/enumerations, develop with pathophysiological mechanisms, and conclude with clinical applications or public health relevance. For (a), cover poison classification first, then snakebite management with Indian context (Big Four snakes), then designer drugs. For (b), integrate molecular pathways with morphology. For (c), emphasize resistance mechanisms and rational cephalosporin use.

Key points expected

  • Part (a): Definition of poison (WHO/forensic standard); classification by source (animal, vegetable, mineral), by target organ, by clinical use; snakebite treatment including first aid (pressure immobilization), antivenom (ASV) administration, complications (anaphylaxis, serum sickness); designer drugs (synthetic cannabinoids, bath salts, fentanyl analogs) with Indian seizure patterns
  • Part (b)(i): Predisposing conditions for oral cancer (tobacco chewing, betel quid with areca nut—specific to Indian subcontinent, HPV-16, alcohol, nutritional deficiency); pathogenesis (field cancerization, multistep carcinogenesis); molecular basis (p53 mutation, EGFR amplification, PI3K/AKT/mTOR pathway); morphology (squamous cell carcinoma types: verrucous, invasive, grading)
  • Part (b)(ii): Pathologic glomerular responses (hypercellularity, basement membrane thickening, hyalinization, sclerosis); pathogenesis of glomerulonephritis (immune complex deposition—post-infectious, anti-GBM, ANCA-associated; complement activation; cytokine-mediated injury)
  • Part (c)(i): Antimicrobial resistance mechanisms (enzymatic inactivation—ESBL, carbapenemases; target modification—MRSA, VRE; efflux pumps; porin loss; biofilm formation; horizontal gene transfer—plasmids, integrons, transposons); mention NDM-1 in Indian context
  • Part (c)(ii): Third generation cephalosporins (cefotaxime, ceftriaxone, ceftazidime, cefoperazone) and fourth generation (cefepime, cefpirome); indications (meningitis, severe sepsis, nosocomial infections, pseudomonal coverage)

Evaluation rubric

DimensionWeightMax marksExcellentAveragePoor
Concept correctness20%10Precise forensic definitions (poison vs. toxin vs. venom); accurate molecular pathology (TP53, EGFR, PI3K/AKT/mTOR for oral cancer); correct immunopathogenesis of GN (immune complex vs. pauci-immune); exact resistance mechanisms with specific enzyme examples (NDM-1, CTX-M, KPC)Generally correct definitions but confused poison/toxin distinction; mentions cancer pathways without specificity; describes GN as 'inflammation' without immune mechanism; lists resistance without mechanistic clarityFundamental errors (calling all snakebites neurotoxic, confusing glomerulonephritis with pyelonephritis, stating cephalosporins are bacteriostatic)
Clinical correlation20%10Integrates Indian epidemiology throughout: Big Four snakes (Naja, Bungarus, Daboia, Echis) with their venom syndromes; oral cancer in India (highest global rates, betel quid chewing); post-streptococcal GN in Indian children; carbapenem resistance in Indian ICUs (NDM-1 origin); ASV dosing based on venom syndrome not speciesMentions Indian context superficially (e.g., 'common in India') without specific data; generic clinical examples without regional relevanceNo Indian context; uses Western epidemiology exclusively; ignores local risk factors like areca nut chewing
Diagram / pathway20%10Clear labeled diagrams: poison classification tree; snakebite management algorithm with ASV indications; oral cancer pathogenesis flowchart (field cancerization → molecular events → invasion); glomerular injury pathways (immune complex deposition → complement activation → cellular injury); resistance mechanism schematic; cephalosporin generation comparison tableMentions diagrams but descriptions incomplete; flowcharts without labels; pathways described textually onlyNo diagrams or tables; purely narrative description where visual representation is essential
Differential / staging20%10For oral cancer: TNM staging mentioned, differential diagnosis (lichen planus, submucous fibrosis, erythroplakia); for glomerular injury: distinguishes minimal change, FSGS, membranous, proliferative GN by morphology and immunofluorescence; for snakebite: differentiates neurotoxic, hemotoxic, myotoxic envenomation syndromesBasic staging mentioned without detail; incomplete differentials; conflates morphological patternsNo staging or differential discussion; fails to distinguish disease subtypes
Management / public-health angle20%10Comprehensive management: snakebite—pressure immobilization technique, ASV dose calculation, adverse reaction management, WHO guidelines; oral cancer—screening (visual inspection), tobacco cessation, HPV vaccination; GN—supportive care, immunosuppression indications; antimicrobial resistance—antibiotic stewardship, CARB-X initiatives, India's Red Line campaign; rational cephalosporin use to prevent resistanceLists treatments without prioritization; misses public health prevention strategies; no mention of stewardshipOutdated treatments (incision-suction for snakebite); no public health perspective; ignores resistance containment strategies

Practice this exact question

Write your answer, then get a detailed evaluation from our AI trained on UPSC's answer-writing standards. Free first evaluation — no signup needed to start.

Evaluate my answer →

More from Medical Science 2021 Paper I